Phase I study of weekly DN-101, a new formulation of calcitriol, in patients with cancer

Tomasz (Tom) Beer, Milind M. Javle, Christopher Ryan, Mark Garzotto, Gilbert N. Lam, Alvin Wong, W. David Henner, Candace S. Johnson, Donald L. Trump

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Background: DN-101 is a new, high-dose, oral formulation of calcitriol under investigation for the treatment of cancer. We sought to evaluate the tolerability and pharmacokinetics (PK) of weekly doses of DN-101 in patients with advanced cancer. Methods: Patients who completed a previously reported single dose escalation study of DN-101 [Beer et al. (2005) Clin Cancer Res 11:7794-7799] were eligible for this continuation weekly dosing study. Cohorts of 3-10 patients were treated at doses of 15, 30, 45, 60, and 75 μg calcitriol. Once 45 μg was established as the maximum tolerated dose (MTD), this cohort was expanded to include 18 patients. Dose limiting toxicity (DLT) was defined as ≥grade 2 hypercalcemia or ≥grade 3 persistent treatment-related toxicities. Results: Thirty-seven patients were recruited. DLT of transient reversible grade 2 hypercalcemia (serum calcium of 11.6-12.5 mg/dL) occurred in two of six patients treated with 60 μg of DN-101. No DLT was observed in the 18 patients who received DN-101 weekly at 45 μg. Overall, DN-101 was well tolerated. The most frequent adverse events were fatigue (27%), hypercalcemia (19%, including five grade 1, two grade 2, and no grade 3 or 4 events), and grade 1 nausea (16%). PK parameters following repeat dosing were comparable to those for the initial dose (n = 4). Conclusion: The MTD for weekly DN-101 was established as 45 μg. The DLTs observed were two episodes of rapidly reversible grade 2 hypercalcemia in two of the six patients treated at 60 μg weekly. Repeat doses of DN-101 at 45 μg weekly are well tolerated and this dose is suitable for studies of weekly DN-101 in cancer patients.

Original languageEnglish (US)
Pages (from-to)581-587
Number of pages7
JournalCancer Chemotherapy and Pharmacology
Volume59
Issue number5
DOIs
StatePublished - Apr 2007

Fingerprint

Calcitriol
Toxicity
Pharmacokinetics
Hypercalcemia
Neoplasms
Maximum Tolerated Dose
Fatigue of materials
Calcium
Nausea
Fatigue
Therapeutics

Keywords

  • Calcitriol
  • Phase I
  • Pulse dosing
  • Vitamin D

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology
  • Oncology

Cite this

Phase I study of weekly DN-101, a new formulation of calcitriol, in patients with cancer. / Beer, Tomasz (Tom); Javle, Milind M.; Ryan, Christopher; Garzotto, Mark; Lam, Gilbert N.; Wong, Alvin; Henner, W. David; Johnson, Candace S.; Trump, Donald L.

In: Cancer Chemotherapy and Pharmacology, Vol. 59, No. 5, 04.2007, p. 581-587.

Research output: Contribution to journalArticle

Beer, Tomasz (Tom) ; Javle, Milind M. ; Ryan, Christopher ; Garzotto, Mark ; Lam, Gilbert N. ; Wong, Alvin ; Henner, W. David ; Johnson, Candace S. ; Trump, Donald L. / Phase I study of weekly DN-101, a new formulation of calcitriol, in patients with cancer. In: Cancer Chemotherapy and Pharmacology. 2007 ; Vol. 59, No. 5. pp. 581-587.
@article{93e111a0f9b041dcaf9a46798a721a97,
title = "Phase I study of weekly DN-101, a new formulation of calcitriol, in patients with cancer",
abstract = "Background: DN-101 is a new, high-dose, oral formulation of calcitriol under investigation for the treatment of cancer. We sought to evaluate the tolerability and pharmacokinetics (PK) of weekly doses of DN-101 in patients with advanced cancer. Methods: Patients who completed a previously reported single dose escalation study of DN-101 [Beer et al. (2005) Clin Cancer Res 11:7794-7799] were eligible for this continuation weekly dosing study. Cohorts of 3-10 patients were treated at doses of 15, 30, 45, 60, and 75 μg calcitriol. Once 45 μg was established as the maximum tolerated dose (MTD), this cohort was expanded to include 18 patients. Dose limiting toxicity (DLT) was defined as ≥grade 2 hypercalcemia or ≥grade 3 persistent treatment-related toxicities. Results: Thirty-seven patients were recruited. DLT of transient reversible grade 2 hypercalcemia (serum calcium of 11.6-12.5 mg/dL) occurred in two of six patients treated with 60 μg of DN-101. No DLT was observed in the 18 patients who received DN-101 weekly at 45 μg. Overall, DN-101 was well tolerated. The most frequent adverse events were fatigue (27{\%}), hypercalcemia (19{\%}, including five grade 1, two grade 2, and no grade 3 or 4 events), and grade 1 nausea (16{\%}). PK parameters following repeat dosing were comparable to those for the initial dose (n = 4). Conclusion: The MTD for weekly DN-101 was established as 45 μg. The DLTs observed were two episodes of rapidly reversible grade 2 hypercalcemia in two of the six patients treated at 60 μg weekly. Repeat doses of DN-101 at 45 μg weekly are well tolerated and this dose is suitable for studies of weekly DN-101 in cancer patients.",
keywords = "Calcitriol, Phase I, Pulse dosing, Vitamin D",
author = "Beer, {Tomasz (Tom)} and Javle, {Milind M.} and Christopher Ryan and Mark Garzotto and Lam, {Gilbert N.} and Alvin Wong and Henner, {W. David} and Johnson, {Candace S.} and Trump, {Donald L.}",
year = "2007",
month = "4",
doi = "10.1007/s00280-006-0299-1",
language = "English (US)",
volume = "59",
pages = "581--587",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "5",

}

TY - JOUR

T1 - Phase I study of weekly DN-101, a new formulation of calcitriol, in patients with cancer

AU - Beer, Tomasz (Tom)

AU - Javle, Milind M.

AU - Ryan, Christopher

AU - Garzotto, Mark

AU - Lam, Gilbert N.

AU - Wong, Alvin

AU - Henner, W. David

AU - Johnson, Candace S.

AU - Trump, Donald L.

PY - 2007/4

Y1 - 2007/4

N2 - Background: DN-101 is a new, high-dose, oral formulation of calcitriol under investigation for the treatment of cancer. We sought to evaluate the tolerability and pharmacokinetics (PK) of weekly doses of DN-101 in patients with advanced cancer. Methods: Patients who completed a previously reported single dose escalation study of DN-101 [Beer et al. (2005) Clin Cancer Res 11:7794-7799] were eligible for this continuation weekly dosing study. Cohorts of 3-10 patients were treated at doses of 15, 30, 45, 60, and 75 μg calcitriol. Once 45 μg was established as the maximum tolerated dose (MTD), this cohort was expanded to include 18 patients. Dose limiting toxicity (DLT) was defined as ≥grade 2 hypercalcemia or ≥grade 3 persistent treatment-related toxicities. Results: Thirty-seven patients were recruited. DLT of transient reversible grade 2 hypercalcemia (serum calcium of 11.6-12.5 mg/dL) occurred in two of six patients treated with 60 μg of DN-101. No DLT was observed in the 18 patients who received DN-101 weekly at 45 μg. Overall, DN-101 was well tolerated. The most frequent adverse events were fatigue (27%), hypercalcemia (19%, including five grade 1, two grade 2, and no grade 3 or 4 events), and grade 1 nausea (16%). PK parameters following repeat dosing were comparable to those for the initial dose (n = 4). Conclusion: The MTD for weekly DN-101 was established as 45 μg. The DLTs observed were two episodes of rapidly reversible grade 2 hypercalcemia in two of the six patients treated at 60 μg weekly. Repeat doses of DN-101 at 45 μg weekly are well tolerated and this dose is suitable for studies of weekly DN-101 in cancer patients.

AB - Background: DN-101 is a new, high-dose, oral formulation of calcitriol under investigation for the treatment of cancer. We sought to evaluate the tolerability and pharmacokinetics (PK) of weekly doses of DN-101 in patients with advanced cancer. Methods: Patients who completed a previously reported single dose escalation study of DN-101 [Beer et al. (2005) Clin Cancer Res 11:7794-7799] were eligible for this continuation weekly dosing study. Cohorts of 3-10 patients were treated at doses of 15, 30, 45, 60, and 75 μg calcitriol. Once 45 μg was established as the maximum tolerated dose (MTD), this cohort was expanded to include 18 patients. Dose limiting toxicity (DLT) was defined as ≥grade 2 hypercalcemia or ≥grade 3 persistent treatment-related toxicities. Results: Thirty-seven patients were recruited. DLT of transient reversible grade 2 hypercalcemia (serum calcium of 11.6-12.5 mg/dL) occurred in two of six patients treated with 60 μg of DN-101. No DLT was observed in the 18 patients who received DN-101 weekly at 45 μg. Overall, DN-101 was well tolerated. The most frequent adverse events were fatigue (27%), hypercalcemia (19%, including five grade 1, two grade 2, and no grade 3 or 4 events), and grade 1 nausea (16%). PK parameters following repeat dosing were comparable to those for the initial dose (n = 4). Conclusion: The MTD for weekly DN-101 was established as 45 μg. The DLTs observed were two episodes of rapidly reversible grade 2 hypercalcemia in two of the six patients treated at 60 μg weekly. Repeat doses of DN-101 at 45 μg weekly are well tolerated and this dose is suitable for studies of weekly DN-101 in cancer patients.

KW - Calcitriol

KW - Phase I

KW - Pulse dosing

KW - Vitamin D

UR - http://www.scopus.com/inward/record.url?scp=33847121998&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33847121998&partnerID=8YFLogxK

U2 - 10.1007/s00280-006-0299-1

DO - 10.1007/s00280-006-0299-1

M3 - Article

C2 - 17066293

AN - SCOPUS:33847121998

VL - 59

SP - 581

EP - 587

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 5

ER -